iSpecimen (ISPC) Proxy Filing summary

Executive summary

• Special Meeting scheduled for October 30, 2025, to address key corporate actions and capital structure changes.

• Proposals include a reverse stock split, increase in authorized shares, approval for large private financings, convertible security amendments, and an equity line of credit.

• Board unanimously recommends approval of all proposals to support continued Nasdaq listing, capital flexibility, and strategic initiatives.

Voting matters and shareholder proposals

• Reverse stock split at a ratio between 1:10 and 1:100, at Board discretion, to maintain Nasdaq listing and increase share price.

• Increase authorized capital stock from 250M to 1B shares to enable future financings and strategic actions.

• Approval for potential issuance of over 20% of outstanding shares in non-public financings, possibly below market price, per Nasdaq rules.

• Amendment to outstanding convertible securities to raise conversion price floor from 50% to 80% of lowest VWAP, reducing dilution risk.

• Authorization for an equity line of credit (ELOC) that may exceed 20% of outstanding shares, providing flexible access to capital.

• Adjournment proposal allows Board to postpone the meeting if necessary.

Board of directors and corporate governance

• Board and management recommend all proposals and oversee proxy solicitation.

• Board retains authority to set reverse split ratio and timing, and to issue additional shares as needed.

• Anti-takeover provisions include staggered board, no cumulative voting, and Board authority to amend bylaws.

• Indemnification and liability protections for directors and officers are in place, with D&O insurance coverage.